Correlation Engine 2.0
Clear Search sequence regions


  • aspergillosis (1)
  • candidiasis (2)
  • host (1)
  • humans (1)
  • patients (1)
  • triazoles (2)
  • Sizes of these terms reflect their relevance to your search.

    Posaconazole is a novel second-generation Triazole oral antifungal agent. It is highly effective in the prophylaxis of invasive fungal infections in immunocompromised patients. It is used as a first-line agent as well as for salvage therapy in invasive fungal infections including aspergillosis, oropharyngeal and esophageal candidiasis. It has a good adverse effect profile. With the rising incidence of invasive fungal infections due to the HIV pandemic and medical advancements in transplantation and cancer therapy, these features make posaconazole a valuable addition in the family of antifungal agents.

    Citation

    M Bhattacharya, K Rajeshwari, B Dhingra. Posaconazole. Journal of postgraduate medicine. 2010 Apr-Jun;56(2):163-7

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 20622401

    View Full Text